Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis

Table 1

Baseline demographic data of subjects with alcoholic cirrhosis.

Variables	Patients with propranolol use, (%)	Patients without propranolol use (number), (%)
Male	20 (90.0)	43 (93.4)	0.743
Age^a			0.858
Superimposed etiology
HBV	6 (27.2)	17 (36.9)	0.367
HCV	1 (4.3)	6 (13.0)	0.365
Autoimmune hepatitis	0	2 (4.3)	0.31
Other CLD	0	0	N/A
Child-Pugh score^a			0.575
Comorbidity
IHD	1 (4.3)	0	0.31
Hypertension	5 (22.7)	11 (23.9)	0.547
COPD	1 (4.3)	1 (2.2)	0.365
DM	5 (22.7)	18 (39.1)	0.468
TB	0	1 (2.2)	0.484
Hyperlipidemia	0	0	N/A
ESRD	0	0	N/A
Cirrhosis duration (months)^a			0.974
Incidence of HCC	1 (4.3)	11 (23.9)	0.043

CLD: chronic liver disease; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; ESRD: end-stage renal disease; HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; IHD: ischemic heart disease; N/A: not available; TB: tuberculosis. ^a.